Report cover image

Drug Formulation Market by Dosage Form (Inhalation Formulations, Oral Formulations, Parenteral Formulations), Technology (Immediate-Release Formulations, Liposomal Formulations, Microsphere Formulations), Therapeutic Area, End User - Global Forecast 2024-

Publisher 360iResearch
Published Apr 17, 2024
Length 193 Pages
SKU # IRE18707615

Description

Drug Formulation Market by Dosage Form (Inhalation Formulations, Oral Formulations, Parenteral Formulations), Technology (Immediate-Release Formulations, Liposomal Formulations, Microsphere Formulations), Therapeutic Area, End User - Global Forecast 2024-2030


The Drug Formulation Market size was estimated at USD 2.42 trillion in 2023 and expected to reach USD 2.55 trillion in 2024, at a CAGR 5.70% to reach USD 3.56 trillion by 2030.

Drug formulation refers to the process through which active pharmaceutical ingredients (APIs) are combined with other substances to create a final medicinal product that is safe, effective, and convenient for patients to use. This technical and intricate process involves choosing suitable excipients to ensure the stability, bioavailability, and optimal performance of the API in the human body. The prevalence of chronic diseases, advancements in drug delivery technologies, and the escalation of personalized medicine have been elevating the need for more drug formulations. Despite the immense potential, drug formulation faces challenges such as the high cost of development, regulatory hurdles, and the complexity of creating formulations that are both stable and acceptable to patients in terms of taste and administration method. Addressing these restraints requires continuous investment in R&D, adopting innovative technologies, and ensuring regulatory strategies are adaptable and efficient. The exploration of novel drug delivery systems such as nanotechnology, sustained-release formulations, and biodegradable polymers is expected to further enhance drug efficacy and patient compliance, potentially transforming the landscape of pharmaceutical care.

Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

193 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and need for effective treatments
5.1.1.2. Government initiatives encouraging drug development and discovery
5.1.1.3. Rise of personalized and tailored medicine and therapies
5.1.2. Restraints
5.1.2.1. Adverse recalls of drugs and medications
5.1.3. Opportunities
5.1.3.1. Advancements in drug delivery and dosage technologies
5.1.3.2. Investments in CDMOs to develop generic drugs
5.1.4. Challenges
5.1.4.1. Complex development and processing of drug formulations
5.2. Market Segmentation Analysis
5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Drug Formulation Market, by Dosage Form
6.1. Introduction
6.2. Inhalation Formulations
6.3. Oral Formulations
6.4. Parenteral Formulations
6.5. Topical Formulations
7. Drug Formulation Market, by Technology
7.1. Introduction
7.2. Immediate-Release Formulations
7.3. Liposomal Formulations
7.4. Microsphere Formulations
7.5. Modified-Release Formulations
7.6. Nanoformulations
7.7. Self-Emulsifying Drug Delivery Systems
7.8. Solid Dispersion Formulations
8. Drug Formulation Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiovascular
8.3. Central Nervous System
8.4. Dermatology
8.5. Endocrinology
8.6. Gastrointestinal
8.7. Immunology
8.8. Infectious Diseases
8.9. Oncology
8.10. Ophthalmology
8.11. Pain Management
8.12. Respiratory
9. Drug Formulation Market, by End User
9.1. Introduction
9.2. Academic & Research Institutions
9.3. Contract Development & Manufacturing Organizations
9.4. Hospitals & Clinics
9.5. Pharmaceutical Companies
10. Americas Drug Formulation Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Drug Formulation Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Drug Formulation Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DRUG FORMULATION MARKET DYNAMICS
FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us